Cerebrolysin vs Dihexa (Oral)
A side-by-side research comparison of Cerebrolysin and Dihexa (Oral) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cerebrolysin | Dihexa (Oral) |
|---|---|---|
| Full name | Cerebrolysin (Brain-Derived Peptide Preparation) | Dihexa (N-hexanoic-Tyr-Ile-(6) Aminohexanoic Amide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Investigational | Research compound |
| Mechanism | Contains fragments mimicking NGF, BDNF, GDNF, CNTF. Enhances synaptic plasticity, promotes neuronal sprouting, reduces amyloid-beta, and stabilizes calcium homeostasis. | Activates hepatocyte growth factor (HGF) / c-Met receptor system in the brain, triggering dendritic spine formation, synaptogenesis, and neuronal survival. This creates new neural pathways for learning and memory. |
| Molecular weight | <10,000 Da (peptide fraction) | 507.63 Da |
| Half-life | 4-6 hours | ~12 hours |
| Bioavailability | High (IM/IV) | ~70% oral, ~60% intranasal |
| Typical dose | 5-30 mL | 10-20 mg |
| Frequency | Daily for 10-20 days | Daily or every other day |
| Route | Intramuscular or IV | Oral capsule or sublingual |
Cerebrolysin reported benefits
- Neurotrophic support
- Stroke recovery
- Memory improvement
- Neuroprotection
- Synaptic plasticity
- Approved in 40+ countries
Dihexa (Oral) reported benefits
- Synaptogenesis (new brain connections)
- Dramatic memory enhancement
- Learning acceleration
- Neuroprotection
- Cognitive recovery after injury
Related comparisons
Research and educational reference only. Not medical advice.